11 results about "Hiv infected" patented technology

The present disclosure relates to methods for determining the magnitude of a subject's immune response against a HIVACAT T-cell immunogen (HTI or “HTI immunogen”) and whether the subject can avoid antiretroviral therapy (ART). These methods are helpful for treating human immunodeficiency virus (HIV) and / or deciding whether to administer, continue or stop antiretroviral therapy in a subject. The present disclosure also relates to antigens, compositions, and kits related to such methods.

The present disclosure is directed to tetrahydroquinazoline derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

The invention discloses application of brusatrolactone A in preparation of a medicine for treating HIV infectious diseases, and belongs to the technical field of biological medicine. The invention provides an application of gall gall lactone A in preparation of a medicine for treating human immunodeficiency virus infectious diseases. The invention also relates to a pharmaceutical composition for treating the HIV infection disease, and the pharmaceutical composition comprises the brusatrolactone A and pharmaceutically acceptable auxiliary materials. A cell model experiment proves that the brusatrolactone A has a remarkable effect on inhibiting HIV (human immunodeficiency virus) from invading cells and inhibiting the replication of the HIV in host cells. The medicament not only expands the medicament selection of HIV infection, but also further expands the application range of the brusatrolactone A.

The purpose of the present invention is to provide a method for detecting whether a subject is infected with AIDS virus (HIV) or is in a latent HIV infection state, or whether the subject is suspected of being infected with HIV or being in a latent HIV infection state.　The present invention provides a method for determining whether a mammalian subject is infected with HIV or is in a latent HIV infection state, or whether the mammalian subject is suspected of being infected with HIV or being in a latent HIV infection state, the method involving: a step for detecting the amount of 3-methylcytidine (m3C) in a sample derived from the subject; and a step for providing information on the detected amount for the determination.

The invention belongs to the technical field of traditional Chinese medicines, and discloses an anti-aging traditional Chinese medicine composition as well as a preparation method and application thereof. The composition is prepared from 12-24 parts of fructus lycii, 12-24 parts of raspberry, 12-15 parts of emblic leafflower fruit, 24 parts of rhizoma polygonati, 12-24 parts of pulp of dogwood fruit, 6 parts of folium mori and 9 parts of rhodiola rosea. The traditional Chinese medicine composition is guided by the theory of traditional Chinese pharmacology, follows the anti-aging core of reinforcing kidney, strengthening spleen and stomach and regulating liver pivot, is combined with clinical practice to screen traditional Chinese medicines with anti-oxidation and anti-inflammatory effects, and can tonify deficiency and strengthen body resistance. Clinical research proves that after the composition intervenes the HIV infected person for 3 months, the composition can significantly reduce the early apoptosis rate of peripheral T cells, improve the Ki67 proliferation index of CD4 + T cells and CD8 + T cells, relieve immune depletion, have no abnormal blood routine and liver and kidney functions, can improve clinical symptoms such as insomnia and weakness, improve the energy level of the body, and provide a safe and effective scheme for premature senility intervention of the HIV infected person.

The application provides a polypeptide molecule for specifically recognizing HIV gp120 protein and an application thereof, and belongs to the technical field of biological medicine. The application provides a lead polypeptide derivative for specifically targeting and combining HIV gp120, wherein the lead polypeptide comprises an amino acid sequence shown in SEQ ID No. 1. The application also provides a lead polypeptide derivative prepared based on the lead polypeptide, and a polypeptide nanoparticle constructed by the lead polypeptide derivative, and both of them have gp120 protein combining capacity. The derivative and the nanoparticle have good virus neutralization inhibition effect. The series of polypeptide molecules can specifically combine with free HIV virus, HIV infected cells and free gp120, so as to block HIV infected cells, delay the AIDS disease process, realize AIDS treatment drug targeted delivery, detection and diagnosis.

The invention discloses application of ipecine in preparation of a medicine for treating HIV infectious diseases, and belongs to the technical field of biological medicines. The invention provides an application of ipecine in preparation of a medicine for treating human immunodeficiency virus infectious diseases. The invention also relates to a pharmaceutical composition for treating the HIV infection diseases, and the pharmaceutical composition comprises ipecine and pharmaceutically acceptable auxiliary materials. A cell model experiment proves that the ipecine has a remarkable effect on inhibiting HIV (Human Immunodeficiency Virus) from invading cells and inhibiting the replication of the HIV in host cells. The drug not only expands the drug selection of HIV infection, but also further expands the application range of the ipecine.

The present invention relates to bispecific antibodies against CD3 and Human Immunodeficiency Virus (HIV) Env, to treat HIV infection.

The invention belongs to the field of medical research, and particularly relates to a method, system and device for evaluating HIV antiviral therapy compliance and a storage medium. The method comprises the following steps: acquiring index data for reflecting ART compliance of an HIV infected person, wherein the index data comprises a nursing retention state, a drug holding rate and a CD4 cell count; constructing a group trajectory model GBTM, and identifying trajectory subgroups of different antiviral treatment compliance in the HIV infected person based on the index data; utilizing a Logistic regression model to evaluate the influence of the demology and ART variable level of different HIV infected persons on the affiliation probability of each trajectory subgroup; utilizing a Cox proportional risk model to evaluate the association between each track subgroup and all-factor death, AIDS death and non-AIDS death; and finally, constructing a dynamic prediction model based on the nursing retention, the drug coverage rate and the CD4 cell counting data by using the combined model, so as to realize real-time early warning of the death risk.

The application of homoharringtonine in the preparation of drugs for treating HIV-infected diseases belongs to the field of biomedical technology. This invention provides the application of homoharringtonine in the preparation of drugs for treating HIV-infected diseases; and a pharmaceutical composition for treating HIV infection, said composition comprising homoharringtonine and pharmaceutically acceptable excipients. This invention demonstrates through cell model experiments that homoharringtonine has a significant effect on inhibiting HIV invasion of cells and inhibiting HIV replication within host cells. This drug not only expands the selection of drugs for HIV infection but also further broadens the application scope of homoharringtonine.

The invention provides a marker composition, a kit and a prediction and evaluation method for evaluating the risk of immune reconstitution insufficiency of an HIV (Human Immunodeficiency Virus) infected person, and the marker composition, the kit and the prediction and evaluation method are used for predicting and evaluating the risk of immune reconstitution insufficiency of the HIV infected person by adopting the combination of three markers of an interferon gamma-induced mononuclear cell chemokine (MIG), a nerve growth factor (NGF) and granzyme B (GZMB). Effective evaluation and auxiliary diagnosis of the risk of incomplete immune reconstitution (INR) of an HIV infected person under long-term anti-retrovirus treatment are realized, the prediction sensitivity, specificity and stability are improved, and a basis is provided for clinical early intervention and individualized management.